Evidence map›Paper›PMID 33580906›Full record

ArticleProteomics. Clinical applications2021

Identification of a serum biomarker signature associated with metastatic prostate cancer.

Venera Kuci Emruli, Leena Liljedahl, Ulrika Axelsson, Corinna Richter, Lisa Theorin, Anders Bjartell, Hans Lilja, Jenny Donovan, David Neal, Freddie C Hamdy and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proteomics. Clinical applications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Venera Kuci EmruliDepartment of Immunotechnology and CREATE Health Translational Cancer Center, Lund University, Lund, Sweden.ORCID 0000-0002-9527-0809
Leena LiljedahlDepartment of Immunotechnology and CREATE Health Translational Cancer Center, Lund University, Lund, Sweden.
Ulrika AxelssonDepartment of Immunotechnology and CREATE Health Translational Cancer Center, Lund University, Lund, Sweden.
Corinna RichterDepartment of Immunotechnology and CREATE Health Translational Cancer Center, Lund University, Lund, Sweden.
Lisa TheorinDepartment of Immunotechnology and CREATE Health Translational Cancer Center, Lund University, Lund, Sweden.
Anders BjartellDepartment of Urology, Skåne University Hospital, Malmö, Sweden.
Hans LiljaDepartment of Translational Medicine, Lund University, Malmö, Sweden.
Jenny DonovanBristol Medical School, University of Bristol, Bristol, UK.
David NealThe Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Freddie C HamdyThe Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Carl A K BorrebaeckDepartment of Immunotechnology and CREATE Health Translational Cancer Center, Lund University, Lund, Sweden.
Lund University · SEUniversity of Oxford · GBMemorial Sloan Kettering Cancer Center · USUniversity of Bristol · GB

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0M
Department of HealthNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629
6 · The paper itself

Abstract

purposeImproved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over-treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease. EXPERIMENTAL

designIn this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non-metastatic PC and patients with metastatic PC, using a recombinant antibody microarray.

resultsA signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified. CONCLUSIONS AND CLINICAL RELEVANCE: The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.

Indexed as

Biomarkers, TumorNeoplasm MetastasisProstatic NeoplasmsAgedCase-Control StudiesHumansMaleMiddle AgedProstate-Specific AntigenBiomarkers, TumorProstate-Specific Antigenaffinity proteomicsantibody microarraysbiomarkerscancerprostate cancer

Identifiers

PMID33580906
PMCPMC9310707
OpenAlexW3126666648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.